CACNA1C -Related Channelopathy Presenting With Adult-Onset Combined Dystonia-Parkinsonism: A Novel Neurological Presentation.

Am J Med Genet AApr 13, 2026 (epub)
Case ReportNeurology

Donatella Ottaviani, Ruggero Bacchin, Arlend Pjeçi et al.

✦ AI-curated · Sources linked

Case in brief

A 66-year-old woman presented with combined dystonia-parkinsonism, including painful tremulous cervical dystonia, blepharospasm, divergent strabismus, hypomimia, mild left-hand dystonic posturing, action tremor, and upper-limb bradykinesia. Genetic testing identified a pathogenic heterozygous CACNA1C nonsense variant, c.481C > T (p.Arg161*), predicted to cause early protein truncation. Botulinum toxin type A provided only partial relief of cervical dystonia; bilateral globus pallidus internus deep brain stimulation was followed by improvement in dystonia.

What made this case unusual

The patient had adult-onset combined dystonia-parkinsonism without a prior neurodevelopmental history, associated with a CACNA1C variant previously reported in individuals with neurodevelopmental phenotypes.

Diagnostic / clinical pearl

CACNA1C-related disease may present with adult-onset movement disorders even without a history of neurodevelopmental disease; genetic testing can help identify this association.

Source

Published in Am J Med Genet A. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.